CoChat
Sign Up
Cited by 140Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCardiovascular Health and Risk Factors

Dyslipidemia and Cardiovascular Disease: Current Knowledge, Existing Challenges, and New Opportunities for Management Strategies

Open access
Du, Zhiyong, Qin, Yanwen·2023·Journal of Clinical Medicine
DOI 10.3390/jcm12010363PMC PMC9820834
Open this paper in CoChat — free accountOpen PDF

Abstract

Cardiovascular disease is the leading cause of morbidity and mortality worldwide, and dyslipidemia is one of the major risk factors [...]

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/jcm12010363

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Dyslipidemia is responsible for approximately 55% of the risk of developing a myocardial infarction.

    “Dyslipidemia is responsible for approximately 55% of the risk of developing a myocardial infarction.”

    From Residual Cardiovascular Risk: Role of Remnants Cholesterol, Monocyte/HDL Ratio and Lipoprotein Ratios on Personalized Cardiovascular Prevention (2024) · cites this paper as [2]

    The paper’s opening section identifies dyslipidemia as a major cardiovascular risk factor and links elevated LDL cholesterol to increased cardiovascular risk. It does not state that dyslipidemia accounts for approximately 55% of myocardial infarction risk; searches for that figure and for myocardial infarction risk found no supporting passage. The numerical and outcome-specific parts of the claim are therefore unsupported. (LLM, conf=0.86)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 37 · Cited by 140

Research works printed but not linked: 27

  1. [1]Pirillo A. Casula M. Olmastroni E. Norata G.D. Catapano A.L. Global epidemiology of dyslipidaemias Nat. Rev. Cardiol. 2021 18 689 700 10.1038/s41569-021-00541-4 33833450 · DOI · Paper page
  2. [3]Ference B.A. Ginsberg H.N. Graham I. Ray K.K. Packard C.J. Bruckert E. Hegele R.A. Krauss R.M. Raal F.J. Schunkert H. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel Eur. Heart J. 2017 38 2459 2472 10.1093/eurheartj/ehx144 28444290 PMC5837225 · DOI · Paper page
  3. [4]Domanski M.J. Tian X. Wu C.O. Reis J.P. Dey A.K. Gu Y. Zhao L. Bae S. Liu K. Hasan A.A. Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk J. Am. Coll. Cardiol. 2020 76 1507 1516 10.1016/j.jacc.2020.07.059 32972526 · DOI · Paper page
  4. [5]Boren J. Chapman M.J. Krauss R.M. Packard C.J. Bentzon J.F. Binder C.J. Daemen M.J. Demer L.L. Hegele R.A. Nicholls S.J. Low-density lipoproteins cause atherosclerotic cardiovascular disease: Pathophysiological, genetic, and therapeutic insights: A consensus statement from the European Atherosclerosis Society Consensus Panel Eur. Heart J. 2020 41 2313 2330 10.1093/eurheartj/ehz962 32052833 PMC7308544 · DOI · Paper page
  5. [6]Mach F. Baigent C. Catapano A.L. Koskinas K.C. Casula M. Badimon L. Chapman M.J. De Backer G.G. Delgado V. Ference B.A. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk Eur. Heart J. 2020 41 111 188 10.1093/eurheartj/ehz455 31504418 · DOI · Paper page
  6. [8]Liao J. Yang L. Zhou L. Zhao H. Qi X. Cui Y. Ouyang D. The NPC1L1 Gene exerts a notable impact on the reduction of low-density lipoprotein cholesterol in response to hyzetimibe: A factorial-designed clinical trial Front. Pharmacol. 2022 13 755469 10.3389/fphar.2022.755469 35359877 PMC8963242 · DOI
  7. [9]Pedro-Botet J. Pinto X. LDL-cholesterol: The lower the better Clin. Investig. Arterioscler. 2019 31 (Suppl. 2) 16 27 10.1016/j.arteri.2019.10.003 31813618 · DOI
  8. [11]Robinson J.G. Farnier M. Krempf M. Bergeron J. Luc G. Averna M. Stroes E.S. Langslet G. Raal F.J. El S.M. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events N. Engl. J. Med. 2015 372 1489 1499 10.1056/NEJMoa1501031 25773378 · DOI · Paper page
  9. [12]Nishikido T. Ray K.K. Non-antibody Approaches to proprotein convertase subtilisin kexin 9 inhibition: siRNA, antisense oligonucleotides, adnectins, vaccination, and new attempts at small-molecule inhibitors based on new discoveries Front. Cardiovasc. Med. 2018 5 199 10.3389/fcvm.2018.00199 30761308 PMC6361748 · DOI
  10. [13]Ballantyne C.M. Bays H. Catapano A.L. Goldberg A. Ray K.K. Saseen J.J. Role of bempedoic acid in clinical practice Cardiovasc. Drugs Ther. 2021 35 853 864 10.1007/s10557-021-07147-5 33818688 PMC8266788 · DOI
  11. [14]Banach M. Duell P.B. Gotto A.J. Laufs U. Leiter L.A. Mancini G. Ray K.K. Flaim J. Ye Z. Catapano A.L. Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia JAMA Cardiol. 2020 5 1124 1135 10.1001/jamacardio.2020.2314 32609313 PMC7330832 · DOI
  12. [16]Tsimikas S. Fazio S. Ferdinand K.C. Ginsberg H.N. Koschinsky M.L. Marcovina S.M. Moriarty P.M. Rader D.J. Remaley A.T. Reyes-Soffer G. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis J. Am. Coll. Cardiol. 2018 71 177 192 10.1016/j.jacc.2017.11.014 29325642 PMC5868960 · DOI
  13. [17]Chapman M.J. Ginsberg H.N. Amarenco P. Andreotti F. Boren J. Catapano A.L. Descamps O.S. Fisher E. Kovanen P.T. Kuivenhoven J.A. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: Evidence and guidance for management Eur. Heart J. 2011 32 1345 1361 10.1093/eurheartj/ehr112 21531743 PMC3105250 · DOI · Paper page
  14. [18]Nordestgaard B.G. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New insights from epidemiology, genetics, and biology Circ. Res. 2016 118 547 563 10.1161/CIRCRESAHA.115.306249 26892957 · DOI · Paper page
  15. [19]Trinder M. DeCastro M.L. Azizi H. Cermakova L. Jackson L.M. Frohlich J. Mancini G. Francis G.A. Brunham L.R. Ascertainment bias in the association between elevated lipoprotein(a) and familial hypercholesterolemia J. Am. Coll. Cardiol. 2020 75 2682 2693 10.1016/j.jacc.2020.03.065 32466883 · DOI
  16. [20]Saleheen D. Haycock P.C. Zhao W. Rasheed A. Taleb A. Imran A. Abbas S. Majeed F. Akhtar S. Qamar N. Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: A mendelian randomisation analysis Lancet Diabetes Endocrinol. 2017 5 524 533 10.1016/S2213-8587(17)30088-8 28408323 PMC5483508 · DOI
  17. [21]Libby P. Lipoprotein (a): A frustrating final frontier in lipid management? JACC Basic Transl. Sci. 2016 1 428 431 10.1016/j.jacbts.2016.08.007 30167530 PMC6113415 · DOI
  18. [22]Toth P.P. Jones S.R. Monsalvo M.L. Elliott-Davey M. Lopez J. Banach M. Effect of evolocumab on non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprotein(a): A pooled analysis of phase 2 and phase 3 studies J. Am. Heart Assoc. 2020 9 e14129 10.1161/JAHA.119.014129 32114889 PMC7335559 · DOI
  19. [24]O’Donoghue M.L. Rosenson R.S. Gencer B. Lopez J. Lepor N.E. Baum S.J. Stout E. Gaudet D. Knusel B. Kuder J.F. Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease N. Engl. J. Med. 2022 387 1855 1864 10.1056/NEJMoa2211023 36342163 · DOI
  20. [25]Duran E.K. Pradhan A.D. Triglyceride-rich lipoprotein remnants and cardiovascular disease Clin. Chem. 2021 67 183 196 10.1093/clinchem/hvaa296 33409533 · DOI
  21. [26]Budoff M. Triglycerides and triglyceride-rich lipoproteins in the causal pathway of cardiovascular disease Am. J. Cardiol. 2016 118 138 145 10.1016/j.amjcard.2016.04.004 27184174 · DOI
  22. [27]Geldenhuys W.J. Lin L. Darvesh A.S. Sadana P. Emerging strategies of targeting lipoprotein lipase for metabolic and cardiovascular diseases Drug Discov. Today 2017 22 352 365 10.1016/j.drudis.2016.10.007 27771332 PMC5482225 · DOI
  23. [30]Gaudet D. Karwatowska-Prokopczuk E. Baum S.J. Hurh E. Kingsbury J. Bartlett V.J. Figueroa A.L. Piscitelli P. Singleton W. Witztum J.L. Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia Eur. Heart J. 2020 41 3936 3945 10.1093/eurheartj/ehaa689 32860031 PMC7750927 · DOI · Paper page
  24. [31]Ahmad Z. Pordy R. Rader D.J. Gaudet D. Ali S. Gonzaga-Jauregui C. Ponda M.P. Shumel B. Banerjee P. Dunbar R.L. Inhibition of angiopoietin-like protein 3 with evinacumab in subjects with high and severe hypertriglyceridemia J. Am. Coll. Cardiol. 2021 78 193 195 10.1016/j.jacc.2021.04.091 34238441 · DOI
  25. [32]Pownall H.J. Rosales C. Gillard B.K. Gotto A.J. High-density lipoproteins, reverse cholesterol transport and atherogenesis Nat. Rev. Cardiol. 2021 18 712 723 10.1038/s41569-021-00538-z 33833449 · DOI
  26. [34]Madsen C.M. Varbo A. Nordestgaard B.G. Novel insights from human studies on the role of high-density lipoprotein in mortality and noncardiovascular disease Arter. Thromb. Vasc. Biol. 2021 41 128 140 10.1161/ATVBAHA.120.314050 33232200 · DOI
  27. [35]Karantas I.D. Okur M.E. Okur N.U. Siafaka P.I. Dyslipidemia management in 2020: An update on diagnosis and therapeutic perspectives Endocr. Metab. Immune Disord. Drug Targets 2021 21 815 834 10.2174/1871530320666200810144004 32778041 · DOI

Authors
Du, Z., & Qin, Y.
Affiliations
Capital Medical University (CN)
Corresponding author
Qin, Yanwen
ORCID
Venue
Journal of Clinical Medicine
Publisher
MDPI AG
Published
2023-01-03
Volume
12
Issue
1
Pages
363
ISSN
2077-0383 (ISSN-L)
DOI
10.3390/jcm12010363
PMC
PMC9820834
OpenAlex
W4313519298
Cited by
140
References
37
Citations by year
2026: 44 · 2025: 54 · 2024: 35 · 2023: 5 · 2022: 1 · 2014: 1
FWCI
36.97
Type
journal article
Language
en
Open access
Licence
Locations
  • Journal of Clinical Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • National Key Research and Development Program of China (2021YFC2500600, 2021YFC2500603, 82100295)
  • National Natural Science Foundation of China (2021YFC2500600, 2021YFC2500603, 82100295)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Risk Factors
Keywords
dyslipidemia, cardiovascular disease, cardiovascular risk factors, dyslipidemia management, lipid-lowering therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review